CITIUS ONCOLOGY INC (CTOR) Stock Analyst Ratings
NASDAQ:CTOR - Nasdaq - US17331Y1091 - Common Stock - Currency: USD
ChartMill assigns a Buy % Consensus number of 43% to CTOR. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 3.06. This target is 8.51% above the current price.
CTOR was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about CTOR.
In the previous month the buy percentage consensus was at a similar level.
CTOR was analyzed by 6 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-05-23 | Maxim Group | Downgrade | Buy -> Hold |
| 2024-11-27 | Maxim Group | Initiate | Buy |
| 2024-08-13 | EF Hutton | Maintains | Buy -> Buy |